Hansa Biopharma AB's total assets for Q2 2025 were kr837.27M, an increase of 18.72% from the previous quarter. SE:HNSA total liabilities were kr1.28B for the fiscal quarter, a -3.81% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.